Información de la revista
Vol. 114. Núm. 4.
Páginas 360-362 (Abril 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 114. Núm. 4.
Páginas 360-362 (Abril 2023)
Case and Research Letter
Acceso a texto completo
Real-Life Experience of Secukinumab in Patients With Hidradenitis Suppurativa
Secukinumab en hidradenitis supurativa, experiencia en practica clínica real
Visitas
2783
F.J. Melgosa Ramos
Autor para correspondencia
fjmr@usal.es

Corresponding author.
, R. García-Ruiz, H. Gegúndez Hernández, A. Mateu-Puchades
Department of dermatology, University Hospital Doctor Peset of Valencia, Spain
Contenido relaccionado
F.J. Melgosa Ramos, R. García-Ruiz, H. Gegúndez Hernández, A. Mateu-Puchades
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo
Dear Editor,

Hidradenitis suppurativa (HS) is a prevalent chronic inflammatory disease with a several impact in patients life style and healthcare system. Adalimumab is the only approved biological therapy for HS and sometimes patients could not have an optimal response to it or contraindication for the use.1–4 In HS patients, the expression of interleukin 17 (IL-17) is increased5,6 and the iL-17 pathway blockade could be a potential therapy to treat HS specially in complex patients after adalimumab failure. In the last years some authors have reported their experience about secukinumab employment for the HS treatment.7,8 Prussick L et al.9,10 published an open label single trial evaluating secukinumab in 9 patients with HS and obtained a clinical regression in 78% of patients without reporting any adverse events. After that Reguiaï Z et al.10 reported their experience in a retrospective study based on a 20 patients cohort treated with secukinumab confirming efficacy (75% of patients achieved HISCR at week 16) safety (despite the report of two cases of bowel disease onset) and a therapeutic response maintenance.

On this topic we decided to contribute with a retrospective study on a cohort of 14 patients diagnosed of severe HS and treated with secukinumab who have previously failed to other classic or biological treatments. Our primary outcome was the proportion of patients who achieved HISCR after 12 weeks of treatment without developing severe adverse events. Secondary outcomes included the evolution of the disease, PGA score, the needed of dose intensification and the optimal response maintenance. We included 14 patients (35% male and 65% female) with a median of 39 years and mass body index (MBI) of 27.6. The main comorbidity found was smoking (85%), and 58.3% had diabetes, hypertension or dyslipemia. One patient had HIV and another had hepatitis B. Depression or anxiety were common (nearly from 60% of patients). Hurley stage was III in all patients (100%). The mean PGA was 4 (severe HS), the mean IHS4 was 15.5, and the mean HS duration was 15.6 years. (Table 1) In all of them HS treatment included multiple long cycles of antibiotics, retinoids, TNF alpha inhibitors (Adalimumab during 5–50 months with mean of 15.7 months including 80mg subcutaneous intensification every 7 or 10 days instead every two weeks in some of them). Three of them also received ustekinumab without optimal response. Secukinumab 300mg subcutaneously was administered weekly for 5 weeks and then every 4 weeks up to 12 weeks.

Table 1.

Cohort Epidemiological Details.

Patient  Gender  Age & (age of onset)  Location (A/I/P/M)a  BMI  Cigarettes/day  Comorbiditiesb  Cardiovascular risk factorsc 
Male  35 (27)  A, I  21.3  10    NO 
Male  61 (15)  A, I  30.4  30  Ischemic cardiopathy  YES 
Female  46 (40)  A, I, M, P  40  Asthma  YES 
Male  31 (19)  I, P  28.4  15  Steatosis  NO 
Male  52 (28)  I, P  22.1  10    YES 
Female  23 (17)  I, M  39.4  Obesity  NO 
Female  49 (No available)  25.9  Psoriasis  YES 
Female  42 (25)  I, P  25.1    NO 
Male  35 (24)  A, P  32.4  20    YES 
10  Female  33 (21)  I, P  26.2  20  Urticaria  YES 
11  Female  46 (18)  I, P  22.6  HBV  NO 
12  Female  51 (43)  A, I, P  28.8  HIV, SAHS  YES 
13  Female  32 (11)  I, P  18.6  Membranous glomerulonephritis, arthritis  NO 
14  Female  55 (26)  A, I  25.2  20    YES 
a

A (axillary) I (inguinal) P (Perineal including anal, genital or both) M (inframammary).

b

Only including relevant comorbidities.

c

Cardiovascular risk factors including diabetes, hypertension and dyslipidemia (all of them or anyone).

After 12 weeks 85% of patients (12/14) achieved a successful HISCR, and decreased their PGA from 4 to 2 also without developing any severe adverse events. Two patients who did not achieve HISCR also improved their PGA score and EVA. After an average follow up of 9 months since secukinumab first administration, two cases of secondary failure were observed in patients who achieved HISCR at first (2/12), decreasing global efficacy to 71.4% (10/14). In two patients (2/10) with optimal response, secukinumab was intensificated every 3 weeks (21 days) instead the classic therapeutic regimen (every 4 weeks) due to a small relapse, keeping the response maintenance. In the two patients who did not achieve HISCR and in one with secondary failure secukinumab intensification rescue firstly every 3 weeks and then every 2 week was tried without success; the other patient with secondary failure was switched to guselkumab. No several adverse events were observed including bowel disease development or several infections (Table 2).

Table 2.

Secukinumab Efficacy and Security in Our Sample.

Patient  Gender  IHS4 pre secukinumaba  HISCR week 12  Secukinumab intensification (300mg)  Response maintenance  Previous biologic treatment  Adverse eventsb 
Male  34  NO  21 days, 15 days  NO  ADALIMUMAB  NO 
Male  24  YES  21 days, 15 days  NO  ADALIMUMAB, USTEKINUMAB  NO 
Female  22  NO  21 days, 15 days  NO  ADALIMUMAB  NO 
Male  YES  21 days  YES  ADALIMUMAB  NO 
Male  YES  NO  YES  ADALIMUMAB  NO 
Female  10  YES  NO  YES  ADALIMUMAB  NO 
Female  10  YES  NO  YES  ADALIMUMAB, USTEKINUMAB  NO 
Female  34  YES  NO  NO  ADALIMUMAB, USTEKINUMAB  NO 
Male  13  YES  NO  YES  ADALIMUMAB  NO 
10  Female  YES  21 days  YES  ADALIMUMAB  NO 
11  Female  YES  NO  YES  ADALIMUMAB  NO 
12  Female  12  YES  NO  YES  ADALIMUMAB  NO 
13  Female  14  YES  NO  YES  ADALIMUMAB  NO 
14  Female  10  YES  NO  PENDING  ADALIMUMAB  NO 
a

300mg weeks 0,1,2,3,4 and then 300mg every 28 days.

b

Severe adverse events including bowel disease development or infection.

In accordance to other reports, our study confirmed the efficacy, response maintenance and safety of secukinumab for the treatment of recalcitrant HS. The global percentage of response (71.4%) might not seem excellent compared with psoriasis but we have to take into account that all patients of the cohort have a severe disease that failed previously to classic therapies and other drugs as adalimumab (or ustekinumab in some cases). We have no data on naïve patients but the response might also be better. Based in our experience, secukinumab intensification (every 3 or 2 weeks) does not seem to be useful in patients who don’t respond firstly but it could be an alternative in well-controlled patients who suffer a temporary relapse. Finally, it is mandatory to understand that molecular pathways of inflammation in HS are more complex than those observed in psoriasis, so it is expected to have temporary relapses despite an overall optimal control during the treatment, being essential to distinguish between outbreak and therapy failure.

Conflict of Interest

The authors declare they have no conflict of interest.

References
[1]
S.R. Goldburg, B.E. Strober, M.J. Payette.
Hidradenitis suppurativa: current and emerging treatments.
J Am Acad Dermatol, 82 (2020), pp. 1061-1082
[2]
S.Y.D. Lim, H.H. Oon.
Systematic review of immunomodulatory therapies for hidradenitis suppurativa.
Biologics, 13 (2019), pp. 53-78
[3]
K. Włodarek, M. Ponikowska, Ł. Matusiak, J.C. Szepietowski.
Biologics for hidradenitis suppurativa: an update.
Immunotherapy, 11 (2019), pp. 45-59
[4]
Ł. Matusiak, G.B. Jemec, J.C. Szepietowski.
Pharmacological development in hidradenitis suppurativa.
Curr Opin Pharmacol, 46 (2019), pp. 65-72
[5]
L. Matusiak, J. Szczęch, A. Bieniek, D. Nowicka-Suszko, J.C. Szepietowski.
Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents.
J Am Acad Dermatol, 76 (2017), pp. 670-675
[6]
B.C. Melnik, S.M. John, W. Chen, G. Plewig.
T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities.
Br J Dermatol, 179 (2018), pp. 260-272
[7]
A. Głowaczewska, J.C. Szepietowski, Ł. Matusiak.
Severe hidradenitis suppurativa successfully treated with secukinumab.
Dermatol Ther, 33 (2020), pp. e13845
[8]
I. Villegas-Romero, C. Collantes-Rodríguez, S. Valenzuela-Ubiña, D. Jiménez-Gallo.
Moderate to severe hidradenitis suppurativa successfully treated with secukinumab.
Actas Dermosifiliogr (Engl Ed), 111 (2020), pp. 696-698
[9]
L. Prussick, B. Rothstein, D. Joshipura, A. Saraiya, Y. Turkowski, R. Abdat, et al.
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.
Br J Dermatol, 181 (2019), pp. 609-611
[10]
Z. Reguiaï, A.C. Fougerousse, F. Maccari, P.A. Bécherel.
Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases).
J Eur Acad Dermatol Venereol, 34 (2020), pp. e750-e751
Copyright © 2022. AEDV
Idiomas
Actas Dermo-Sifiliográficas
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?